Glepaglutide: Protection of compound patent until 2026 (Zealand Pharma) - Nov 4, 2022 - Corporate Presentation: Protection of patent related to dosing regime until 2038; Protection of patent related to clinical formulation until 2039
Patent • Short Bowel Syndrome
|